Boston Scientific Settles With SEC On 1997/98 Japan Sales Irregularities
This article was originally published in The Gray Sheet
Executive SummaryA settlement reached between Boston Scientific and the Securities and Exchange Commission in connection with improperly recorded sales by the company's Japanese operation does not include a fine.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.